Have a feature idea you'd love to see implemented?
Let us know!
KALV KalVista Pharmaceuticals Inc
Price (delayed)
$7.4
Market cap
$365.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.69
Enterprise value
$328.79M
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary
Highlights
KalVista Pharmaceuticals's debt has decreased by 29% YoY and by 6% QoQ
KALV's equity is down by 22% since the previous quarter but it is up by 17% year-on-year
KALV's quick ratio is down by 21% since the previous quarter but it is up by 6% year-on-year
KalVista Pharmaceuticals's net income has plunged by 55% YoY and by 10% from the previous quarter
The EPS has contracted by 21% YoY and by 3.1% from the previous quarter
Key stats
What are the main financial stats of KALV
Market
Valuations
Earnings
Shares outstanding
49.42M
Market cap
$365.69M
Enterprise value
$328.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.39
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$156.39M
EBIT
-$156.39M
EBITDA
-$155.51M
Free cash flow
-$123.06M
Per share
Balance sheet
Liquidity
EPS
-$3.69
EPS diluted
-$3.69
Free cash flow per share
-$2.64
Book value per share
$3.1
Revenue per share
$0
TBVPS
$3.44
Total assets
$160.83M
Total liabilities
$26.84M
Debt
$4.68M
Equity
$133.99M
Working capital
$130.1M
Debt to equity
0.03
Current ratio
6.87
Quick ratio
6.13
Net debt/EBITDA
0.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-88.1%
Return on equity
-103.9%
Return on invested capital
-120.9%
Return on capital employed
-112.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KALV stock price
How has the KalVista Pharmaceuticals stock price performed over time
Intraday
-1.6%
1 week
-15.53%
1 month
-14.84%
1 year
-42.9%
YTD
-12.63%
QTD
-12.63%
Financial performance
How have KalVista Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$171.63M
Net income
-$156.39M
Gross margin
N/A
Net margin
N/A
KalVista Pharmaceuticals's net income has plunged by 55% YoY and by 10% from the previous quarter
KALV's operating income is down by 46% YoY and by 10% QoQ
Growth
What is KalVista Pharmaceuticals's growth rate over time
Valuation
What is KalVista Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.39
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 21% YoY and by 3.1% from the previous quarter
The P/B is 37% lower than the last 4 quarters average of 3.8 and 8% lower than the 5-year quarterly average of 2.6
KALV's equity is down by 22% since the previous quarter but it is up by 17% year-on-year
Efficiency
How efficient is KalVista Pharmaceuticals business performance
KalVista Pharmaceuticals's return on equity has shrunk by 55% YoY and by 7% QoQ
The ROA has shrunk by 50% YoY and by 7% QoQ
KalVista Pharmaceuticals's return on invested capital has decreased by 22% YoY and by 3.5% QoQ
Dividends
What is KALV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KALV.
Financial health
How did KalVista Pharmaceuticals financials performed over time
KALV's quick ratio is down by 21% since the previous quarter but it is up by 6% year-on-year
KALV's total assets is down by 20% QoQ but it is up by 16% YoY
KalVista Pharmaceuticals's debt is 97% lower than its equity
The debt to equity has plunged by 50% YoY
KalVista Pharmaceuticals's debt has decreased by 29% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.